<SEC-DOCUMENT>0001193125-20-319222.txt : 20201217
<SEC-HEADER>0001193125-20-319222.hdr.sgml : 20201217
<ACCEPTANCE-DATETIME>20201216184358
ACCESSION NUMBER:		0001193125-20-319222
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201216
FILED AS OF DATE:		20201217
DATE AS OF CHANGE:		20201216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		201393719

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d27429d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated December&nbsp;16, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="d27429dex991.htm">Immutep Upscales Efti Manufacturing </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;16, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d27429dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27429dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Upscales Efti Manufacturing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>December</B><B></B><B>&nbsp;16, 2020 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has prioritised the recommencement of the process of scaling up the manufacturing of its lead product candidate
eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This follows the very encouraging interim results Immutep announced from its efti clinical
trials at SITC (10 November 2020) and SABS (10 December 2020) and will be funded by the recent conversion of warrants on Immutep. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is planning to
increase the efti manufacturing process from 200L to 2,000L capacity bioreactors at the WuXi Biologics manufacturing plant (Mashan site, Wuxi, China), with the major scale up steps taking place throughout 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Chen, CEO of WuXi Biologics said: <I>&#147;We are very pleased to be moving the scale up process forward for efti with Immutep. WuXi Biologics and
Immutep have been working together for many years and we are excited to continue supporting them as they advance towards registration for efti.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Voigt, CEO of Immutep said:<I> &#147;Following the very encouraging interim Overall Survival data announced last week from our largest clinical trial,
AIPAC, we have activated our plans to upscale the manufacturing of efti to 2,000L <FONT STYLE="white-space:nowrap">single-use</FONT> bioreactors</I><B> </B><I>to prepare for potential commercial manufacturing and potential registration trials in
multiple indications. WuXi Biologics is an important and long-term partner for us with excellent technical and commercial capabilities. We are entering 2021 in a very strong position, both financially and operationally.&#148; </I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products,
including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep
Limited</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27429dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s <U>website www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g27429dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27429dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0
M\4 <'X@U2^OQ,UMN73X7\LLIQN;W]JYYMO8\^M4G+X=C)ATJX,<4DD,T6^4*
MKE,*!W.:E1,53DU=G7Z1JJQ:FVE->"[7;NBFSDGCE2>_UK6+L['="I:7)>YT
M8K4Z!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H RK_Q%I>F7D=I=W:Q3/@@$$XSZD=/QH U <C(H 6@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H 9("8V ."1P:!/8\KLKF2PU",2%Q&
MDH,D8/!P>>*Y$VF>5&3C.QW6KZOIITN>$W<3/(A0*#DY(XR!TKH<HVL=U2I'
MEL<CH-M)'XFMH@59HW))0Y& /6L(*TCCHJU5(]+KJ/4"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6\\'>*=0G\Z["S2XV[FE&<>E &U\0$>+PQIT<GWUE4-]=AH T?AY_P BNO\
MUV?^E $?Q&V?\(VF[&[SUV_7!_I0!#\--W]B76<[?M''_?(S0!VM !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 =J &&-">5!/N*!-)[BE5(P
M0#[&BP %5?N@#Z4#VV$9%;D@'ZTK(328H  P.@ICV$,:$Y*C/TI:"LGT%*J1
M@X/UHL,%55^Z /I3V%:PA1&/(!I6!I,4  8' ICV$*(3DJ,_2E9"LNP[CUIC
M(IK:WN,":&.7'9U!_G0 D5G:P']S!%'_ +B 4 3# H 9+!#.NV:))%]'4$4
M-AM+:WX@@CB_W% _E0!+[4 0S6=K<$&>WBE(_OH#_.@!T5M!;C;#$D0]$4#^
M5 ''_$O_ ) =I_U\#_T$T 3> 8(I_"JK+&LB^<_# $=J .JAMX;==L,21CT1
M0* ): "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MLG=GL3C;C\: &V\:3Z;=!LR6ZNY@9B3\N/7TSG'MB@!I1H=-TS[. '9T)R2
M25.<T 1W+W'V36_-(5U@^78QP/D/2@!S/$-'U V[V^\0L?\ 1Y,_PG&?2@!]
MANM]0E61$ME$(8(KEE?GEN0,8Z'ZCVH BLKFX6^2YEAF2*\)&7(VKWCP,Y'R
MYSQU(H 6"UGN+F21$5"MTQ,WF'<5#?=QCD8XY- $\<,O]J-;&0_9TQ< 9.<D
MGY?H""?R]* ,#XE_\@.T_P"O@?\ H)H M?#S_D5U_P"NS_TH ZN@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !D4 &10 9% !D4 &10 9% !D4 &10 9
M% !D4 &10 9% !D4 &10 9% !D4 &10 9% !D4 &10 9% !D4 &10 9% !D4
M &10 9% !D4 &10 9% !D4 &10 9% !D4 &10 9% !D4 &10 9% !D4 &10
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MM1S2#FJ!_:&L?\_5W_WVU'-(.:H']H:Q_P _5W_WVU'-(.:H']H:Q_S]7?\
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M<T@YJ@?VAK'_ #]7?_?;4<T@YJ@?VAK'_/U=_P#?;4<T@YJ@?VAK'_/U=_\
M?;4<T@YJ@?VAK'_/U=_]]M1S2#FJ!_:&L?\ /U=_]]M1S2#FJ!_:&L?\_5W_
M -]M1S2#FJ!_:&L?\_5W_P!]M1S2#FJ!_:&L?\_5W_WVU'-(.:H']H:Q_P _
M5W_WVU'-(.:H']H:Q_S]7?\ WVU'-(.:H']H:Q_S]7?_ 'VU'-(.:H']H:Q_
MS]7?_?;4<T@YJ@?VAK'_ #]7?_?;4<T@YJ@?VAK'_/U=_P#?;4<T@YJ@?VAK
M'_/U=_\ ?;4<T@YJ@?VAK'_/U=_]]M1S2#FJ!_:&L?\ /U=_]]M1S2#FJ!_:
M&L?\_5W_ -]M1S2#FJ!_:&L?\_5W_P!]M1S2#FJ!_:&L?\_5W_WVU'-(.:H'
M]H:Q_P _5W_WVU'-(.:H']H:Q_S]7?\ WVU'-(.:H']H:Q_S]7?_ 'VU'-(.
M:H']H:Q_S]7?_?;4<T@YJ@?VAK'_ #]7?_?;4<T@YJ@?VAK'_/U=_P#?;4<T
M@YJ@?VAK'_/U=_\ ?;4<T@YJ@?VAK'_/U=_]]M1S2#FJ!_:&L?\ /U=_]]M1
MS2#FJ!_:&L?\_5W_ -]M1S2#FJ!_:&L?\_5W_P!]M1S2#FJ!_:&L?\_5W_WV
MU'-(.:H']H:Q_P _5W_WVU'-(.:H']H:Q_S]7?\ WVU'-(.:H']H:Q_S]7?_
M 'VU'-(.:H>HX'I76>ML&!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8%
M!@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &
M!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8%
M !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4
M&!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8
M% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% !@4
B &!0 8% !@4 &!0 8% !@4 &!0 8% !@4 &!0 8% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
